Chase Doyle


Authored Items

What Do We Still Need to Know About Adolescent and Young Adult Survivorship?

May 2017, Vol 7, No 5 - Survivorship

As a result of the differences in biology, access to care, and psychosocial and socioeconomic circumstances, adolescent and young adult (AYA) patients with cancer face distinct challenges compared with their adult counterparts. At the 2017 Cancer Survivorship Symposium, Emily S. Tonorezos, MD, MPH, General Internist, Adult Long-Term Follow-Up Program, Memorial Sloan Kettering Cancer Center, New York, NY, discussed gaps in research and treatment in this vulnerable patient population, while proposing solutions to improve AYA survivorship care. [ Read More ]

Reducing Disparities in Survivorship Care

April 2017, Vol 7, No 4 - Survivorship

Surviving cancer is the start of a new journey for many individuals. Cancer survivors face a multitude of challenges, including the prevention of new and recurrent cancers; interventions for illnesses secondary to cancer and its treatment; concerns about employment, insurance, and disability; and coordination between specialists and primary care providers. These challenges are compounded by the need to ensure appropriate, culturally sensitive delivery of care to vulnerable patient populations, said Margaret Q. Rosenzweig, PhD, FNP-BC, AOCNP, FAAN, Professor of Acute and Tertiary Care, University of Pittsburgh School of Nursing, PA, at the 2017 Cancer Survivorship Symposium. [ Read More ]

Rapid Adoption of Novel Oncology Drugs Improves Overall Survival

April 2017, Vol 7, No 4 - Survivorship

Innovation takes time, especially when it comes to cancer research. However, delays in the adoption of novel oncology treatments can have a significant impact on patient health, reported Jason Shafrin, PhD, Director of Healthcare Quality and Value-Based Research Methods, and Senior Research Economist, Precision Health Economics, Los Angeles, CA, who presented the results of a geographic-based analysis of claims data at the 2017 Cancer Survivorship Symposium. [ Read More ]

New Value Model Incorporates Long-Term Adverse Effects of Cancer Drugs

February 2017, Vol 7, No 2 - ASH 2016 Highlights

A new economic model suggests that overall survival and drug toxicity profiles are insufficient for assessing the value of a drug. According to a study that incorporated late adverse events in advanced Hodgkin lymphoma, a more comprehensive benefit-to-risk ratio of a drug requires an understanding of its long-term health implications, said Ohad Oren, MD, Pennsylvania Hospital, University of Pennsylvania, Philadelphia, at the 2016 American Society of Hematology meeting. [ Read More ]

Measuring Outcomes to Improve Quality

March 2016, Vol 6, No 3 - Reimbursement

Medicare is poised to incorporate new quality metrics as a guide for payments. At ASH 2015, Helen Burstin, MD, MPH, Chief Scientific Officer, National Quality Forum, Washington, DC, discussed the need for measures and reporting systems that reflect patient care and care coordination. “The purpose of measurement is [ Read More ]

Cost of Regorafenib versus Benefit Analyzed in Patients with Metastatic Colorectal Cancer

April 2015, Vol 5, No 3 - Gastrointestinal Cancers Symposium

According to a recent cost-effectiveness analysis, third-line therapy with regorafenib (Stivarga) in patients with previously treated metastatic colorectal cancer (CRC) far ­exceeded accepted willingness-to-pay thresholds based on incremental cost-effectiveness ratio (ICER) and quality-adjusted life-years (QALYs). Presented at the 2015 Gastrointestinal [ Read More ]